STAT

FDA approves first new drug developed for women with postpartum depression

The FDA approved Sage Therapeutics' brexanolone, the first drug specifically targeted to treat postpartum depression.

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readSelf-Improvement
Opinion: Quitting Smoking Is Hard. Mindfulness Hacks The Habit Loop, Offering A New Approach
Smoking hijacks the brain's reward-based learning system. Each time a smoker smokes, it reinforces a brain pathway that says, "This is great, do it again." Mindfulness techniques can break the…
STAT5 min readSociety
After Ebola Spills Into Uganda, WHO Decides Against Emergency Declaration
The Ebola outbreak in the Democratic Republic of the Congo still doesn’t constitute a global health emergency, the WHO said Friday.
STAT3 min readSociety
Opinion: Shopping Blindly For Post-acute Care Is A Recipe For Disaster
The notion that sick, frail, or elderly patients and their families can somehow figure out on their own the best choice for post-acute care must be discarded.